Paper Details

  1. Home
  2. Paper Details

Patients with ankylosing spondylitis treatment by golimumab: a systematic review and meta-analysis.

Author: LiuChanghao, RoyBrotendu Shekhar, Sayed AbdullaJami, ShiJiandang, ZhanwenZhou

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Retracted PublicationCases where a publication has been formally withdrawn due to the discovery of serious errors or misconduct.

Overview

A review of nine studies with 6363 patients with ankylosing spondylitis (AS) found that golimumab was effective in treating AS. The higher dose (100 mg) was more effective but also increased the incidence of serious adverse events (SAE).
Paper Details　
Original Abstract of the Article :
PURPOSE: The goal of this study was to review relevant randomized controlled trials in order to determine the clinical efficacy of golimumab in the treatment of ankylosing spondylitis (AS). METHODS: Using appropriate keywords, we identified relevant studies using PubMed, Cochrane and Embase. Key pe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00586-020-06466-9

データ提供：米国国立医学図書館（NLM）

Golimumab: A Potential Oasis in the Desert of Ankylosing Spondylitis

Ankylosing spondylitis is a chronic inflammatory disease that can be a debilitating condition, much like navigating a treacherous desert landscape. This research explores the potential of golimumab, a biologic drug, as a treatment option for ankylosing spondylitis. It’s like discovering a new wellspring of hope in the desert, offering a potential source of relief and healing.

The researchers conducted a systematic review and meta-analysis of relevant clinical trials, combining evidence from multiple studies to assess the effectiveness of golimumab in treating ankylosing spondylitis. It's like mapping out a new trade route through the desert, carefully considering the terrain and potential obstacles. The analysis provides a comprehensive overview of golimumab's efficacy, safety, and potential benefits.

A Promising Treatment Option

The study's findings reveal that golimumab demonstrates significant efficacy in treating ankylosing spondylitis. It's like finding a lush oasis in the midst of a barren desert, offering respite and rejuvenation. The drug was found to improve various measures of disease activity and quality of life, providing hope for patients struggling with this challenging condition.

Navigating the Treatment Landscape

The study provides valuable insights into the use of golimumab for ankylosing spondylitis, offering guidance for clinicians and patients. It’s like having a seasoned desert guide, leading the way through complex and challenging terrain. The research outlines potential benefits, risks, and dosage considerations, helping to navigate the treatment landscape.

Dr. Camel's Conclusion

This study highlights the potential of golimumab as a promising treatment option for ankylosing spondylitis. It's like discovering a new wellspring of hope in the desert, offering a source of relief and healing for patients. This research provides valuable insights into the treatment landscape, paving the way for a brighter future for individuals living with this challenging condition.

Date :
  1. Date Completed 2021-06-23
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

32447529

DOI: Digital Object Identifier

10.1007/s00586-020-06466-9

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.